Quality Payment Program Measures Data |
Back to Merit-based Incentive Payment System |
| Measure ID | NQF ID | National Quality Strategy Domain | Title | High Priority | Measure Type | Submission Methods | Speciality Measure Sets | |
|---|---|---|---|---|---|---|---|---|
| ACRAD34 | Patient Safety | Multi-strata weighted average for 3 CT Exam Types: Overall Percent of CT exams for which Dose Length Product is at or below the size-specific diagnostic reference level (for CT Abdomen-pelvis with contrast/single phase scan, CT Chest without contrast/single phase scan and CT Head/Brain without contrast/single phase scan) | Outcome | Registry | Details | |||
| ACRAD36 | Communication and Care Coordination | Incidental Coronary Artery Calcification Reported on Chest CT | Process | Registry | Details | |||
| ACRAD37 | Communication and Care Coordination | Interpretation of CT Pulmonary Angiography (CTPA) for Pulmonary Embolism | Process | Registry | Details | |||
| ACRAD38 | Patient Safety | Use of Low Dose Cranial CT or MRI Examinations for Patients with Ventricular Shunts | Process | Registry | Details | |||
| ACRAD39 | Patient Safety | Use of Low Dose CT Studies for Adults with Suspicion of Urolithiasis or Nephrolithiasis | Process | Registry | Details | |||
| ACRAD40 | Communication and Care Coordination | Use of Structured Reporting in Prostate MRI | Process | Registry | Details | |||
| ACRAD41 | Communication and Care Coordination | Use of Quantitative Criteria for Oncologic FDG PET Imaging | Process | Registry | Details | |||
| ACRAD42 | Efficiency and Cost Reduction | Surveillance Imaging for Liver Nodules <10mm in Patients at Risk for Hepatocellular Carcinoma (HCC) | Process | Registry | Details | |||
| AQUA14 | Effective Clinical Care | Stones: Repeat Shock Wave Lithotripsy (SWL) within 6 months of treatment | Outcome | Registry | Details | |||
| AQUA15 | Patient Safety | Stones: Urinalysis documented 30 days before surgical stone procedures | Process | Registry | Details | |||
| AQUA16 | Effective Clinical Care | Non-Muscle Invasive Bladder Cancer: Repeat Transurethral Resection of Bladder Tumor (TURBT) for T1 disease | Process | Registry | Details | |||
| AQUA17 | Effective Clinical Care | Non-Muscle Invasive Bladder Cancer: Initiation of BCG within 3 months of diagnosis of high-grade T1 bladder cancer and/or CIS | Process | Registry | Details | |||
| AQUA18 | Effective Clinical Care | Non-Muscle Invasive Bladder Cancer: Early surveillance cystoscopy within 4 months of initial diagnosis | Process | Registry | Details | |||
| AQUA19 | Effective Clinical Care | Diagnosis of Type of Azoospermia and Diagnostic Testing for Obstructive Azoospermia | Process | Registry | Details | |||
| AQUA21 | Effective Clinical Care | Appropriate Management of Obstructive Azoospermia | Process | Registry | Details | |||
| AQUA22 | Effective Clinical Care | Bone imaging and soft tissue imaging within 30 days (before or after) of diagnosis of metastatic CRPC | Process | Registry | Details | |||
| AQUA24 | Effective Clinical Care | Testosterone and PSA levels checked for CRPC patients | Process | Registry | Details | |||
| AQUA26 | Efficiency and Cost Reduction | Benign Prostate Hyperplasia Care: Benign Prostate Hyperplasia | Process | Registry | Details | |||
| AQUA32 | Effective Clinical Care | Hypogonadism: Laboratory evaluation conducted within 6 months of starting testosterone replacement | Process | Registry | Details | |||
| AQUA8 | Effective Clinical Care | Hospital admissions/complications within 30 days of TRUS Biopsy | Outcome | Registry | Details |